Details of Disease

General Information of Disease (ID: DIS3VLDH)

Disease Name Thyroid cancer
Synonyms
thyroid gland neoplasm; neoplasm of thyroid gland; thyroid gland cancer; malignant tumour of thyroid gland; malignant tumour of thyroid; malignant tumour of the thyroid gland; malignant tumour of the thyroid; malignant tumor of thyroid gland; malignant tumor of thyroid; malignant tumor of the thyroid gland; malignant tumor of the thyroid; malignant thyroid tumour; malignant thyroid tumor; malignant thyroid neoplasm; malignant thyroid gland tumour; malignant thyroid gland tumor; malignant thyroid gland neoplasm; malignant neoplasm of thyroid gland; malignant neoplasm of thyroid; malignant neoplasm of the thyroid gland; malignant neoplasm of the thyroid; cancer of thyroid gland
Disease Class 2D10: Thyroid cancer
Definition A malignant neoplasm involving the thyroid gland
Disease Hierarchy
DISAT1Z9: Advanced cancer
DISLVKMD: Thyroid tumor
DISKTBM1: Malignant endocrine neoplasm
DIS3VLDH: Thyroid cancer
ICD Code
ICD-11
ICD-11: 2D10
ICD-10
ICD-10: C73
ICD-9
ICD-9: 193
Expand ICD-9
193
Disease Identifiers
MONDO ID
MONDO_0002108
UMLS CUI
C0007115
MedGen ID
2869
SNOMED CT ID
363478007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 9 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cabozantinib DMIYDT4 Approved Small molecular drug [1]
Doxorubicin DMVP5YE Approved Small molecular drug [2]
Lenvatinib DMB1IU4 Approved Small molecular drug [3]
Levothyroxine DMHN027 Approved Small molecular drug [4]
Liothyronine DM6IR3P Approved Small molecular drug [5]
Nicotinamide DMUPE07 Approved Small molecular drug [6]
Selpercatinib DMZR15V Approved NA [7]
Sorafenib DMS8IFC Approved Small molecular drug [8]
Thyrotropin Alfa DMMYLTI Approved NA [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
QGE-031 DME2P45 Phase 3 NA [10]
Selumetinib DMC7W6R Phase 3 Small molecular drug [11]
GI-6207 DM72O6F Phase 2 NA [12]
AIC100 DMSPBOW Phase 1 CAR T Cell Therapy [13]
CYTO-403 DM12PTB Phase 1 NA [14]
Demogastrin DMTULGS Phase 1 NA [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 2 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ITRI-305 DMWTDS8 Investigative NA [16]
Recombinant TSH superagonists DMJQ7XD Investigative NA [17]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 93 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CALCA TTVSFJW Limited Biomarker [18]
CDH6 TT9QHUK Limited Biomarker [19]
DUSP5 TTZN92A Limited Biomarker [20]
GJB3 TTVRQ8L Limited Altered Expression [21]
KSR1 TTHL1TV Limited Posttranslational Modification [22]
LASP1 TTZJA87 Limited Biomarker [23]
LGALS3 TTFPQV7 Limited Biomarker [24]
MAP2K7 TT6QY3J Limited Genetic Variation [25]
MAP4K4 TT6NI13 Limited Altered Expression [26]
MUC15 TTGQ6MI Limited Biomarker [27]
S1PR2 TTVSMOH Limited Biomarker [28]
SCN10A TT90XZ8 Limited Biomarker [29]
SLC6A9 TTHJTF7 Limited Biomarker [30]
STOML2 TTOI329 Limited Altered Expression [31]
TSG101 TTHU7JA Limited Biomarker [32]
YES1 TT0SQ8J Limited Altered Expression [33]
ATIC TT9NVXQ Disputed Biomarker [34]
SORT1 TTRX9AV Disputed Biomarker [35]
ARAF TT5TURO moderate Genetic Variation [36]
BCAT2 TTF9OQ6 moderate Altered Expression [37]
CCNE2 TTLDRGX moderate Altered Expression [38]
CNTN1 TTPR8FK moderate Biomarker [39]
IL32 TTD4G7L moderate Biomarker [40]
LIMK1 TTWL9TY moderate Biomarker [41]
MAPKAP1 TTWDKCL moderate Altered Expression [42]
MVD TTE5J6X moderate Altered Expression [43]
PRKCQ TT1MS7X moderate Biomarker [44]
SDHD TTVH9W8 moderate Genetic Variation [45]
TPCN1 TTODQE2 moderate Biomarker [46]
TRPC1 TTA76X0 moderate Biomarker [47]
ACVR1B TTPKHTZ Strong Altered Expression [48]
AKT3 TTO6SGY Strong Biomarker [49]
ALK TTPMQSO Strong Biomarker [50]
ARG2 TTV1AG6 Strong Biomarker [51]
BUB1 TT78309 Strong Genetic Variation [52]
CBX7 TTBN3HC Strong Altered Expression [53]
CDH5 TTXLCFO Strong Posttranslational Modification [54]
CDK5 TTL4Q97 Strong Biomarker [55]
CXCR1 TTMWT8Z Strong Altered Expression [56]
CXXC5 TTVS4C3 Strong Altered Expression [57]
CYP24A1 TT82UI1 Strong Biomarker [58]
F9 TTFEZ5Q Strong Genetic Variation [59]
FGFR4 TT1KX2S Strong Biomarker [60]
GPER1 TTDSB34 Strong Biomarker [61]
GRK2 TTAZ3MN Strong Altered Expression [62]
HIPK2 TTOB49C Strong Biomarker [63]
IL1R2 TT51DEV Strong Genetic Variation [64]
KLB TTARBVH Strong Altered Expression [65]
KRAS TTM8FR7 Strong Biomarker [66]
KRT19 TT3JF9E Strong Altered Expression [67]
LGR4 TTY6C71 Strong Altered Expression [68]
MCM7 TT1RM3F Strong Altered Expression [69]
NCOA4 TT8OY02 Strong Altered Expression [39]
NR1D1 TTAD1O8 Strong Genetic Variation [70]
NRAS TTW2R9X Strong Biomarker [71]
NTRK3 TTXABCW Strong Biomarker [72]
OGFR TT6IEYX Strong Biomarker [73]
PPARGC1B TTKSQ3W Strong Genetic Variation [74]
PPM1D TTENJAB Strong Genetic Variation [75]
PRKAR1A TTNAHEX Strong Genetic Variation [72]
PTPRJ TTWMKXP Strong Genetic Variation [76]
RET TT4DXQT Strong Biomarker [72]
RGS4 TTGTKX9 Strong Biomarker [77]
RHBDF2 TTH1ZOP Strong Biomarker [78]
SERPINB5 TT1KW50 Strong Posttranslational Modification [79]
SLC1A3 TT8WRDA Strong Altered Expression [80]
SLC26A4 TT7X02I Strong Genetic Variation [81]
SLC5A5 TTW7HI9 Strong Biomarker [82]
SLCO2B1 TTDL3UZ Strong Biomarker [83]
SORD TTLSRBZ Strong Genetic Variation [84]
SSTR3 TTJX3UE Strong Altered Expression [85]
STC1 TTDLUER Strong Biomarker [86]
TACSTD2 TTP2HE5 Strong Biomarker [87]
TEP1 TTQGAVX Strong Biomarker [88]
THRA TTTSEPU Strong Genetic Variation [70]
THRB TTGER3L Strong Biomarker [89]
TKTL1 TTNQ1J3 Strong Biomarker [90]
TP53BP1 TTX4UE9 Strong Altered Expression [91]
TXNIP TTTLDZK Strong Biomarker [92]
VCP TTHNLSB Strong Altered Expression [82]
WNK1 TTJ9UMX Strong Posttranslational Modification [93]
CCR6 TTFDB30 Definitive Biomarker [94]
ELAVL1 TTPC9D0 Definitive Biomarker [95]
FGF19 TTGCH11 Definitive Biomarker [60]
FOLH1 TT9G4N0 Definitive Altered Expression [96]
GAP43 TTSGLN5 Definitive Biomarker [97]
HMGA1 TTBA219 Definitive Biomarker [98]
IL13RA2 TTMPZ7V Definitive Biomarker [99]
PAK1 TTFN95D Definitive Biomarker [100]
PKM TT4LOT8 Definitive Biomarker [101]
SLIT2 TTDWK85 Definitive Biomarker [102]
STK4 TTCPLVN Definitive Biomarker [103]
TPO TT52XDZ Definitive Biomarker [104]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC16A2 DTQ8MP1 Limited Altered Expression [105]
SLC5A8 DTE3TAW Strong Genetic Variation [81]
------------------------------------------------------------------------------------
This Disease Is Related to 10 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYB5R3 DE4A3BL Limited Biomarker [106]
HIF1AN DEY1CBW Limited Biomarker [107]
UPP1 DEFZWAX moderate Altered Expression [108]
BAAT DERA3OF Strong Genetic Variation [70]
CYP1A1 DE6OQ3W Strong Altered Expression [109]
GGCT DEKW6PB Strong Biomarker [110]
GSTM1 DEYZEJA Strong Biomarker [111]
GSTT1 DE3PKUG Strong Genetic Variation [111]
NNMT DECVGJ3 Strong Altered Expression [112]
AKR1C2 DEOY5ZM Definitive Altered Expression [113]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
This Disease Is Related to 231 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AFM OTPOR8IO Limited Biomarker [114]
AGPS OTFBFPV4 Limited Biomarker [115]
AKAP4 OTL4Z99V Limited Biomarker [116]
ANO5 OTOW8R6H Limited Altered Expression [117]
ATG9B OTJMJZW8 Limited Biomarker [118]
BASP1 OTF4VS5G Limited Altered Expression [119]
BHLHE41 OTY9GJ1Y Limited Biomarker [120]
BID OTOSHSHU Limited Biomarker [118]
BTG2 OTZF6K1H Limited Altered Expression [121]
C14orf93 OTMHTPMZ Limited Biomarker [122]
CCL15 OTOGZ85M Limited Biomarker [123]
CETN1 OTGQ8JOZ Limited Altered Expression [106]
CITED1 OTUJQ3VL Limited Biomarker [124]
COPZ1 OTJXGQQW Limited Biomarker [125]
DIAPH1 OTZBYPLH Limited Biomarker [106]
DIPK2A OTL1DBIM Limited Biomarker [106]
EHF OTY6TPWD Limited Altered Expression [126]
EIF4A3 OTYYFE7K Limited Biomarker [127]
FAM107B OT5RG4J0 Limited Altered Expression [128]
FHOD3 OT1WUBQX Limited Genetic Variation [129]
FLCN OTVM78XM Limited Genetic Variation [130]
FXYD5 OT81DIOD Limited Altered Expression [131]
FZD8 OTZ9IRFL Limited Altered Expression [132]
GATAD2A OTFM8D3O Limited Biomarker [133]
HMGN4 OTD7GPRL Limited Biomarker [134]
HNRNPD OT5UO1FA Limited Altered Expression [135]
HORMAD2 OTL2ENWI Limited Altered Expression [136]
HUWE1 OTFH6BJS Limited Biomarker [137]
IFT88 OTDR3VBD Limited Altered Expression [138]
IGF2BP3 OTB97VIK Limited Altered Expression [139]
IL17RB OT0KDNSF Limited Altered Expression [140]
ING5 OTRNNSFM Limited Biomarker [141]
KIR2DS5 OTXLEN11 Limited Genetic Variation [142]
LETM1 OT8N4MRU Limited Altered Expression [143]
LRP4 OTO4M459 Limited Altered Expression [144]
MREG OT0LUIRG Limited Biomarker [145]
NCOA5 OTOGWTWB Limited Biomarker [146]
NFIL3 OTQH9HM3 Limited Biomarker [147]
NRARP OTMYHUV2 Limited Biomarker [148]
NRCAM OT80HHQ2 Limited Biomarker [149]
PAX8 OTRPD9MI Limited Biomarker [150]
PCBP1 OTHN0TD7 Limited Altered Expression [151]
PEG3 OTHQW98S Limited Biomarker [152]
PIWIL2 OT1PXQIF Limited Biomarker [153]
POT1 OTNBXJCQ Limited Genetic Variation [154]
POU5F1B OT0FKQ51 Limited Genetic Variation [155]
PROX1 OT68R6IO Limited Biomarker [156]
RAB11A OTC4FW0J Limited Altered Expression [157]
RASSF1 OTEZIPB7 Limited Posttranslational Modification [158]
RCC1 OT25AGMB Limited Genetic Variation [159]
RNASE1 OTKZ7CO9 Limited Altered Expression [160]
SDF4 OTQ7WFYW Limited Altered Expression [106]
SLC35F2 OTSAD4EQ Limited Biomarker [161]
SPRY4 OT2VK9N0 Limited Biomarker [162]
SRGAP1 OTL89HGW Limited Genetic Variation [163]
SRP72 OTPV73W7 Limited Altered Expression [129]
SYTL2 OTUIOWKL Limited Altered Expression [31]
TCP1 OT1MGUX9 Limited Biomarker [164]
TCTN1 OTG5KEV8 Limited Biomarker [165]
TIMM44 OTXP7MXN Limited Autosomal dominant [166]
TIMP4 OT8A68SW Limited Altered Expression [167]
TINAGL1 OTZZO56M Limited Altered Expression [168]
TRIM29 OT2DNESG Limited Altered Expression [169]
TRIM44 OT0B1T2B Limited Biomarker [170]
TTF1 OT4K90WD Limited Altered Expression [171]
DCTN6 OTI8PIN9 Disputed Biomarker [172]
DDT OTF5HTYL Disputed Biomarker [173]
ECM1 OT1K65VW Disputed Altered Expression [174]
GPD2 OTV232Y7 Disputed Biomarker [175]
IFI27 OTI2XGIT Disputed Biomarker [172]
MYO1F OTOAV4AR Disputed Biomarker [176]
NCOA1 OTLIUJQD Disputed Altered Expression [177]
NEMP1 OTWN3S47 Disputed Biomarker [178]
PELI1 OTMLBCLC Disputed Biomarker [179]
PRDM6 OTKY12D9 Disputed Biomarker [179]
PRIMA1 OT9ITT3P Disputed Posttranslational Modification [180]
RASAL1 OTAHUNN7 Disputed Biomarker [181]
TCIM OTARUXQF Disputed Genetic Variation [182]
TICAM2 OTK7GIJ5 Disputed Biomarker [172]
TMED7 OTONO8E6 Disputed Biomarker [172]
ABCE1 OTH19LOA moderate Biomarker [183]
ADGRE2 OTUYJVYG moderate Altered Expression [184]
ADGRE5 OTTSB84Q moderate Altered Expression [184]
ATP5F1E OTMPLAIS moderate Altered Expression [185]
BCAM OTHZOPSD moderate Biomarker [37]
CARD11 OTRCTLYC moderate Altered Expression [186]
CCNG2 OTII38K2 moderate Biomarker [187]
CPSF2 OTU6QXZE moderate Biomarker [188]
CRYGD OTW29JC4 moderate Genetic Variation [189]
CTDSPL OTZJ0CZK moderate Biomarker [190]
DUSP4 OT6WAO12 moderate Biomarker [191]
FOXE1 OT5IR5IT moderate Altered Expression [192]
GRB14 OTFET2YM moderate Altered Expression [193]
HLTF OTRX2OSF moderate Biomarker [194]
HOXC10 OT5WF17M moderate Biomarker [195]
MT1G OTAV1OCR moderate Altered Expression [196]
NIBAN1 OTYOLI12 moderate Altered Expression [197]
PA2G4 OT7IG7HT moderate Biomarker [181]
PDZK1IP1 OTWA6M5K moderate Altered Expression [198]
PPP6C OTR1STMJ moderate Biomarker [44]
RBX1 OTYA1UIO moderate Biomarker [199]
REC8 OT6JAVXE moderate Altered Expression [200]
RTN4IP1 OTHUZANE moderate Altered Expression [201]
SASH1 OTQA8BD4 moderate Biomarker [202]
SERPINA5 OTTZXPGD moderate Biomarker [191]
SLIT3 OTU8MKEU moderate Biomarker [203]
SOX17 OT9H4WWE moderate Posttranslational Modification [204]
SPC24 OT1HVYV4 moderate Altered Expression [205]
TBX15 OTAZ9QDX moderate Biomarker [206]
ABI3BP OTW8DN50 Strong Biomarker [207]
AKAP9 OT7Z2YRP Strong Biomarker [208]
ANKRD36B OT3MW415 Strong Biomarker [209]
ATF1 OT251CI0 Strong Altered Expression [210]
BAG3 OTVXYUDQ Strong Altered Expression [211]
CCDC6 OTXRQDYG Strong Genetic Variation [59]
CCDC80 OTOZSYEM Strong Biomarker [212]
CDC23 OTC4O83E Strong Biomarker [213]
CITED2 OT812TV7 Strong Biomarker [214]
CLEC4D OTT7X1UC Strong Genetic Variation [215]
CREB3L2 OT09MHV0 Strong Genetic Variation [216]
DACT2 OTNLCC0K Strong Posttranslational Modification [217]
DUSP6 OT4H6RKW Strong Biomarker [20]
EIF1AX OTWG2LAB Strong Biomarker [218]
ERRFI1 OT7VZ2IZ Strong Biomarker [219]
FBLIM1 OTFHXMON Strong Altered Expression [220]
FGF3 OT9PK2SI Strong Biomarker [221]
FOXA1 OTEBY0TD Strong Altered Expression [222]
GADD45G OT8V1J4M Strong Biomarker [223]
GINS2 OT974IYI Strong Biomarker [214]
GOPC OTRBGH71 Strong Altered Expression [220]
GORASP1 OTQS91S7 Strong Posttranslational Modification [93]
GOT2 OT6XBWN0 Strong Biomarker [224]
GYPA OTABU4YV Strong Genetic Variation [225]
HABP2 OTAUIPW0 Strong Genetic Variation [226]
HNRNPF OTSMBXMF Strong Biomarker [227]
ID3 OTUULW5Z Strong Altered Expression [228]
IGFBP4 OT2HZRBD Strong Biomarker [229]
INF2 OT8ZM13C Strong Biomarker [230]
INPP4B OTLROA7G Strong Genetic Variation [231]
INTS2 OT2N5TCK Strong Biomarker [221]
ITGA3 OTBCH21D Strong Biomarker [232]
IYD OT8BQWTE Strong Altered Expression [233]
KLLN OTV3FPH0 Strong Genetic Variation [234]
MADD OTUFYVGG Strong Biomarker [235]
MASTL OTQ7YKK5 Strong Biomarker [236]
MMP20 OT16S5S3 Strong Altered Expression [237]
MR1 OTZU3XX7 Strong Altered Expression [238]
MRO OT5U38CP Strong Biomarker [239]
MT1M OTVT8PLU Strong Altered Expression [240]
NDRG2 OT5L6KD7 Strong Altered Expression [241]
NECTIN1 OTTE5ZR6 Strong Altered Expression [242]
NKX2-1 OTCMEJTA Strong Genetic Variation [59]
NPC2 OTE9UEJC Strong Biomarker [243]
PEA15 OTKCKTSX Strong Altered Expression [244]
PJA2 OT45TMC4 Strong Altered Expression [245]
PPP1R15A OTYG179K Strong Altered Expression [246]
PROK1 OT8S7RUG Strong Biomarker [247]
PTCH2 OTOQ0K9V Strong Biomarker [248]
PTMA OT2W4T1M Strong Biomarker [249]
PTMS OT9PS4Q0 Strong Biomarker [249]
PTPRF OTH5KF2D Strong Biomarker [46]
PTTG1 OTIMYS4W Strong Biomarker [250]
PTTG1IP OTX21QTE Strong Biomarker [250]
RAD52 OT0OTDHI Strong Genetic Variation [251]
RASIP1 OTCRY2AN Strong Altered Expression [252]
RASSF10 OTGB7EBG Strong Posttranslational Modification [253]
RASSF2 OT2JHDO4 Strong Biomarker [254]
RBBP4 OTG3BT3M Strong Biomarker [255]
RCAN1 OT1MVXC7 Strong Altered Expression [256]
REV1 OTHIKICX Strong Altered Expression [257]
RGCC OTYJMLWM Strong Biomarker [213]
RLN2 OTY3OG71 Strong Biomarker [258]
RNF139 OT0PR1X5 Strong Biomarker [259]
RPL36A OT1LYV85 Strong Biomarker [219]
RSPO2 OT3HHXU0 Strong Altered Expression [68]
SAGE1 OT4H6FFA Strong Biomarker [260]
SDHB OTRE1M1T Strong Genetic Variation [261]
SDS OT5WTJ2M Strong Genetic Variation [84]
SEC23B OT2NFSIQ Strong Genetic Variation [262]
SEC62 OTCWEL5F Strong Altered Expression [263]
SGSM3 OTIB1P8A Strong Biomarker [264]
SIRT4 OT5S0J23 Strong Altered Expression [265]
SIRT7 OT5M4OT4 Strong Altered Expression [266]
SLURP1 OT89YD2E Strong Genetic Variation [267]
SMURF1 OT5UIZR8 Strong Biomarker [268]
SNX5 OT6ZOWMU Strong Biomarker [269]
SOD3 OTIOZQAB Strong Altered Expression [270]
SPAG9 OT45AHMB Strong Altered Expression [271]
SSX2 OT2Z6RLL Strong Altered Expression [272]
STK3 OTLNSCQD Strong Biomarker [254]
STRN OTLOZL5I Strong Altered Expression [273]
SYT1 OTVTPOI6 Strong Posttranslational Modification [93]
TAF1 OTDYS5G4 Strong Biomarker [224]
TAS2R38 OTX5MM36 Strong Genetic Variation [59]
TCEAL4 OTX24CQI Strong Altered Expression [274]
TFF3 OTJJDRTU Strong Altered Expression [275]
TMEM184C OTCA2HUW Strong Altered Expression [276]
TMPRSS4 OTCCGY2K Strong Altered Expression [174]
TOMM20 OT76TPR2 Strong Biomarker [277]
TSPAN13 OTCS9BZY Strong Altered Expression [278]
TTF2 OT5LJOWM Strong Biomarker [279]
ALX4 OTNS9A29 Definitive Altered Expression [280]
BMP8A OT1997IN Definitive Altered Expression [281]
CAVIN2 OTFHHDRU Definitive Biomarker [282]
DEUP1 OTXLM86J Definitive Altered Expression [283]
ETFA OTXX61VZ Definitive Biomarker [284]
FUCA1 OTW71IK4 Definitive Altered Expression [285]
HCP5 OTV0YRI8 Definitive Biomarker [286]
IGSF1 OT3XD6U2 Definitive Altered Expression [287]
IQGAP1 OTZRWTGA Definitive Altered Expression [288]
KIF22 OTY6X6BL Definitive Biomarker [289]
KLHL14 OTYOS55H Definitive Biomarker [290]
LIMD2 OTSIFTD8 Definitive Biomarker [291]
LRIG1 OTY5HZN5 Definitive Genetic Variation [292]
MIEF1 OTFSP3FS Definitive Biomarker [103]
NOC2L OTNT7R33 Definitive Biomarker [293]
NOVA1 OT6A9KHY Definitive Biomarker [294]
OBP2A OTBIJ5TI Definitive Biomarker [289]
PARP4 OTXBK59G Definitive Biomarker [295]
PATZ1 OT0X9WGR Definitive Biomarker [296]
PKHD1L1 OTREFCAA Definitive Biomarker [297]
PSME3 OTSTC4YY Definitive Biomarker [298]
RAP1B OTHEIIMM Definitive Altered Expression [299]
RAP1GAP OTC31ONQ Definitive Biomarker [300]
SHOC2 OTUNQ2CT Definitive Biomarker [301]
SOSTDC1 OTAKDNSM Definitive Altered Expression [147]
SPANXA1 OTMK3QIS Definitive Biomarker [302]
TFAP2B OTR1T8E9 Definitive Altered Expression [303]
TFCP2L1 OT7QIJ0X Definitive Biomarker [304]
TPM3 OT5RU5G6 Definitive Biomarker [72]
TRIP13 OTFM3TI9 Definitive Altered Expression [305]
------------------------------------------------------------------------------------
⏷ Show the Full List of 231 DOT(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).
2 Doxorubicin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
4 Levothyroxine FDA Label
5 Liothyronine FDA Label
6 Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review. Biomolecules. 2021 Oct 28;11(11):1594.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Sorafenib FDA Label
9 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020898.
10 ClinicalTrials.gov (NCT02336425) Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma. U.S. National Institutes of Health.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 ClinicalTrials.gov (NCT04420754) Study of AIC100 in Relapsed/Refractory Thyroid Cancer. U.S. National Institutes of Health.
14 Clinical pipeline report, company report or official report of Cytocom
15 99mTc-Demogastrin 2 for CCK 2-receptor scintigraphy in medullary thyroid carcinoma. J Nucl Med. 2008; 49 (Supplement 1):115P.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 255).
18 The positive clinical therapeutically effects of Escin on advanced thyroid cancer.Cancer Med. 2017 May;6(5):937-943. doi: 10.1002/cam4.1031. Epub 2017 Apr 4.
19 Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy.Oncogene. 2017 Feb 2;36(5):667-677. doi: 10.1038/onc.2016.237. Epub 2016 Jul 4.
20 DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.PLoS One. 2017 Sep 14;12(9):e0184861. doi: 10.1371/journal.pone.0184861. eCollection 2017.
21 Ginsenoside improves papillary thyroid cancer cell malignancies partially through upregulating connexin 31.Kaohsiung J Med Sci. 2018 Jun;34(6):313-320. doi: 10.1016/j.kjms.2017.12.006. Epub 2018 Jan 17.
22 KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.J Mol Endocrinol. 2015 Apr;54(2):115-24. doi: 10.1530/JME-14-0270. Epub 2015 Jan 21.
23 Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion.Oncol Res. 2017 Jul 5;25(6):879-886. doi: 10.3727/096504016X14785415155643. Epub 2016 Nov 17.
24 Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.J Nucl Med. 2019 Jun;60(6):770-776. doi: 10.2967/jnumed.118.219105. Epub 2018 Oct 25.
25 A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Clin Cancer Res. 2019 Sep 15;25(18):5475-5484. doi: 10.1158/1078-0432.CCR-18-1881. Epub 2019 Jun 11.
26 Functional analysis of a novel, thyroglobulin-embedded microRNA gene deregulated in papillary thyroid carcinoma.Sci Rep. 2017 Aug 30;7(1):9942. doi: 10.1038/s41598-017-10318-w.
27 Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways.Oncogenesis. 2018 Nov 12;7(11):85. doi: 10.1038/s41389-018-0094-y.
28 Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2.PLoS One. 2018 May 7;13(5):e0196992. doi: 10.1371/journal.pone.0196992. eCollection 2018.
29 New Treatment of Medullary and Papillary Human Thyroid Cancer: Biological Effects of Hyaluronic Acid Hydrogel Loaded With Quercetin Alone or in Combination to an Inhibitor of Aurora Kinase.J Cell Physiol. 2016 Aug;231(8):1784-95. doi: 10.1002/jcp.25283. Epub 2016 Feb 2.
30 LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.Oncotarget. 2017 Apr 4;8(14):22954-22967. doi: 10.18632/oncotarget.14578.
31 Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.APMIS. 2016 Apr;124(4):271-7. doi: 10.1111/apm.12505. Epub 2016 Jan 11.
32 Tumor Susceptibility Gene 101 Mediates Anoikis Resistance of Metastatic Thyroid Cancer Cells.Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):473-483. doi: 10.21873/cgp.20106.
33 Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.FEBS J. 2016 Jun;283(12):2326-39. doi: 10.1111/febs.13741. Epub 2016 May 12.
34 The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.J Endocrinol Invest. 2018 Nov;41(11):1275-1282. doi: 10.1007/s40618-018-0862-8. Epub 2018 Mar 15.
35 Neurotrophin Receptors TrkA, p75(NTR), and Sortilin Are Increased and Targetable in Thyroid Cancer.Am J Pathol. 2018 Jan;188(1):229-241. doi: 10.1016/j.ajpath.2017.09.008. Epub 2017 Oct 14.
36 RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.Mol Cell Endocrinol. 2015 Nov 5;415:64-75. doi: 10.1016/j.mce.2015.08.006. Epub 2015 Aug 8.
37 DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.Blood Cells Mol Dis. 2013 Mar;50(3):161-5. doi: 10.1016/j.bcmd.2012.10.009. Epub 2012 Nov 17.
38 Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2.Oncotarget. 2015 Oct 13;6(31):31780-91. doi: 10.18632/oncotarget.5566.
39 Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12473-81. eCollection 2015.
40 Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.Cell Oncol (Dordr). 2019 Oct;42(5):691-703. doi: 10.1007/s13402-019-00457-9. Epub 2019 Jun 14.
41 MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1.PLoS One. 2014 May 23;9(5):e96103. doi: 10.1371/journal.pone.0096103. eCollection 2014.
42 SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.Surgery. 2014 Dec;156(6):1542-8; discussion 1548-9. doi: 10.1016/j.surg.2014.08.095. Epub 2014 Nov 11.
43 Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).Tumour Biol. 2014 Jul;35(7):6521-9. doi: 10.1007/s13277-014-1868-2. Epub 2014 Apr 1.
44 Identification of thyroid carcinoma related genes with mRMR and shortest path approaches.PLoS One. 2014 Apr 9;9(4):e94022. doi: 10.1371/journal.pone.0094022. eCollection 2014.
45 Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells.Hum Mol Genet. 2017 Apr 1;26(7):1365-1375. doi: 10.1093/hmg/ddx037.
46 Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.PLoS One. 2019 Feb 26;14(2):e0206309. doi: 10.1371/journal.pone.0206309. eCollection 2019.
47 Transient Receptor Potential Canonical 1 (TRPC1) Channels as Regulators of Sphingolipid and VEGF Receptor Expression: IMPLICATIONS FOR THYROID CANCER CELL MIGRATION AND PROLIFERATION.J Biol Chem. 2015 Jun 26;290(26):16116-31. doi: 10.1074/jbc.M115.643668. Epub 2015 May 13.
48 Activin A and activin receptors in thyroid cancer.Thyroid. 2001 Jan;11(1):3-14. doi: 10.1089/10507250150500603.
49 miR-217 inhibits proliferation, migration, and invasion via targeting AKT3 in thyroid cancer.Biomed Pharmacother. 2017 Nov;95:1718-1724. doi: 10.1016/j.biopha.2017.09.074. Epub 2017 Oct 6.
50 Characterization of thyroid cancer driven by known and novel ALK fusions.Endocr Relat Cancer. 2019 Nov;26(11):803-814. doi: 10.1530/ERC-19-0325.
51 Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors.Free Radic Biol Med. 2010 Sep 15;49(6):997-1007. doi: 10.1016/j.freeradbiomed.2010.06.006. Epub 2010 Jun 11.
52 Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1.Clin Endocrinol (Oxf). 2002 Mar;56(3):341-50. doi: 10.1046/j.1365-2265.2002.01475.x.
53 The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients.Eur J Cancer. 2010 Aug;46(12):2304-13. doi: 10.1016/j.ejca.2010.05.011. Epub 2010 Jun 9.
54 Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.Cancer Res. 1998 May 15;58(10):2063-6.
55 Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser on STAT3 in prostate cancer cells.Am J Physiol Endocrinol Metab. 2013 Oct 15;305(8):E975-86. doi: 10.1152/ajpendo.00615.2012. Epub 2013 Aug 13.
56 Multiple anti-tumor effects of Reparixin on thyroid cancer.Oncotarget. 2017 May 30;8(22):35946-35961. doi: 10.18632/oncotarget.16412.
57 RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.
58 CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells.Exp Ther Med. 2018 Oct;16(4):2821-2830. doi: 10.3892/etm.2018.6536. Epub 2018 Jul 27.
59 Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population.Carcinogenesis. 2016 Jul;37(7):677-684. doi: 10.1093/carcin/bgw047. Epub 2016 Apr 28.
60 Alteration in the serum concentrations of FGF19, FGFR4 and Klotho in patients with thyroid cancer.Cytokine. 2018 May;105:32-36. doi: 10.1016/j.cyto.2018.02.013. Epub 2018 Feb 10.
61 GPER1 in the thyroid: A systematic review.Life Sci. 2020 Jan 15;241:117112. doi: 10.1016/j.lfs.2019.117112. Epub 2019 Nov 29.
62 Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2.Cell Physiol Biochem. 2018;51(2):729-745. doi: 10.1159/000495329. Epub 2018 Nov 21.
63 The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.PLoS One. 2011;6(6):e20665. doi: 10.1371/journal.pone.0020665. Epub 2011 Jun 17.
64 Genetic polymorphisms in IL1R1 and IL1R2 are associated with susceptibility to thyroid cancer in the Chinese Han population.J Gene Med. 2019 Jun;21(6):e3093. doi: 10.1002/jgm.3093. Epub 2019 May 27.
65 Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer.Cancers (Basel). 2019 Aug 12;11(8):1154. doi: 10.3390/cancers11081154.
66 Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.
67 BRAF(V600E)-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT.Oncol Lett. 2019 Jul;18(1):927-935. doi: 10.3892/ol.2019.10360. Epub 2019 May 14.
68 Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.Oncotarget. 2017 Nov 25;8(70):114980-114994. doi: 10.18632/oncotarget.22692. eCollection 2017 Dec 29.
69 Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.World J Surg. 2006 May;30(5):767-74. doi: 10.1007/s00268-005-0308-2.
70 Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms.Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):638-42. doi: 10.1158/1055-9965.EPI-04-0424.
71 TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.
72 Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.Eur J Endocrinol. 2019 Apr 1;180(4):235-241. doi: 10.1530/EJE-18-0653.
73 Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.
74 Mitochondrial metabolism is inhibited by the HIF1-MYC-PGC-1 axis in BRAF V600E thyroid cancer.FEBS J. 2019 Apr;286(7):1420-1436. doi: 10.1111/febs.14786. Epub 2019 Mar 5.
75 Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.Endocrine. 2019 Jan;63(1):94-100. doi: 10.1007/s12020-018-1762-6. Epub 2018 Sep 29.
76 Single nucleotide polymorphism analysis in the human phosphatase PTPrj gene using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.Rapid Commun Mass Spectrom. 2004;18(19):2249-54. doi: 10.1002/rcm.1617.
77 Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma.Oncol Rep. 2008 Jul;20(1):105-21.
78 Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.BMJ Case Rep. 2019 Apr 1;12(4):e227910. doi: 10.1136/bcr-2018-227910.
79 Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.Oncogene. 2004 Feb 5;23(5):1117-24. doi: 10.1038/sj.onc.1207211.
80 CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression.Biochem Biophys Res Commun. 2019 Mar 26;511(1):87-91. doi: 10.1016/j.bbrc.2019.02.023. Epub 2019 Feb 13.
81 Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 2013 Oct;67(8):723-30.
82 Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.Cancer Res. 2020 Jan 1;80(1):102-115. doi: 10.1158/0008-5472.CAN-19-1957. Epub 2019 Oct 31.
83 Expression of OATP family members in hormone-related cancers: potential markers of progression.PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.
84 Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet. 2012 Jan 15;21(2):300-10. doi: 10.1093/hmg/ddr459. Epub 2011 Oct 6.
85 Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62. doi: 10.1210/jcem.82.6.4013.
86 Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1.Oncol Rep. 2016 Jan;35(1):552-8. doi: 10.3892/or.2015.4358. Epub 2015 Oct 29.
87 Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma.Eur Thyroid J. 2019 Jan;8(1):1-6. doi: 10.1159/000494430. Epub 2018 Nov 22.
88 Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death.Hum Mol Genet. 2001 Feb 1;10(3):251-8. doi: 10.1093/hmg/10.3.251.
89 Thyroid Hormone Receptor- (TR) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.Endocrinology. 2016 Aug;157(8):3278-92. doi: 10.1210/en.2015-2046. Epub 2016 Jun 2.
90 Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.Invest New Drugs. 2009 Aug;27(4):297-303. doi: 10.1007/s10637-008-9174-8. Epub 2008 Sep 20.
91 Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny.Endocr Relat Cancer. 2019 Aug;26(8):713-725. doi: 10.1530/ERC-19-0176.
92 TXNIP overexpression suppresses proliferation and induces apoptosis in SMMC7221 cells through ROS generation and MAPK pathway activation.Oncol Rep. 2017 Jun;37(6):3369-3376. doi: 10.3892/or.2017.5577. Epub 2017 Apr 18.
93 AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.Cancers (Basel). 2019 Jun 7;11(6):785. doi: 10.3390/cancers11060785.
94 Role of chemokine receptors in thyroid cancer and immunotherapy.Endocr Relat Cancer. 2019 Aug;26(8):R465-R478. doi: 10.1530/ERC-19-0163.
95 The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.Sci Rep. 2019 May 14;9(1):7374. doi: 10.1038/s41598-019-43894-0.
96 Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.Oncotarget. 2018 Jan 4;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 9.
97 Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.J Cell Mol Med. 2019 Dec;23(12):7974-7984. doi: 10.1111/jcmm.14460. Epub 2019 Sep 30.
98 TGF-1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.Int J Oncol. 2017 May;50(5):1567-1578. doi: 10.3892/ijo.2017.3958. Epub 2017 Apr 7.
99 IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5573-5584. doi: 10.1210/jc.2019-00040.
100 MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
101 Activation of AMPK promotes thyroid cancer cell migration through its interaction with PKM2 and -catenin.Life Sci. 2019 Dec 15;239:116877. doi: 10.1016/j.lfs.2019.116877. Epub 2019 Oct 25.
102 The role of Slit2 as a tumor suppressor in thyroid cancer.Mol Cell Endocrinol. 2019 Mar 1;483:87-96. doi: 10.1016/j.mce.2019.01.010. Epub 2019 Jan 12.
103 Mst1 overexpression combined with Yap knockdown augments thyroid carcinoma apoptosis via promoting MIEF1-related mitochondrial fission and activating the JNK pathway.Cancer Cell Int. 2019 May 22;19:143. doi: 10.1186/s12935-019-0860-8. eCollection 2019.
104 TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations.Int J Cancer. 2013 Dec 15;133(12):2843-51. doi: 10.1002/ijc.28317. Epub 2013 Jul 13.
105 Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism.Eur J Endocrinol. 2017 Sep;177(3):243-250. doi: 10.1530/EJE-17-0279. Epub 2017 Jun 2.
106 RAGE Mediates the Pro-Migratory Response of Extracellular S100A4 in Human Thyroid Cancer Cells.Thyroid. 2015 May;25(5):514-27. doi: 10.1089/thy.2014.0257. Epub 2015 Apr 3.
107 Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer.Anticancer Res. 2015 Apr;35(4):2049-54.
108 Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.J Cell Mol Med. 2019 Nov;23(11):7438-7448. doi: 10.1111/jcmm.14612. Epub 2019 Sep 9.
109 Gene Expression of CYP1A1 and its Possible Clinical Application in Thyroid Cancer Cases.Asian Pac J Cancer Prev. 2016;17(7):3477-82.
110 Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma.J BUON. 2018 Jan-Feb;23(1):234-243.
111 Glutathione S-transferase M1, T1, and P1 polymorphisms and thyroid cancer risk: a meta-analysis.Cancer Epidemiol. 2012 Dec;36(6):e333-40. doi: 10.1016/j.canep.2012.06.002. Epub 2012 Jul 4.
112 Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.Mol Endocrinol. 2005 Feb;19(2):527-39. doi: 10.1210/me.2004-0215. Epub 2004 Oct 14.
113 Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma.J Cancer. 2019 Jun 9;10(15):3543-3552. doi: 10.7150/jca.28364. eCollection 2019.
114 Afamin promotes glucose metabolism in papillary thyroid carcinoma.Mol Cell Endocrinol. 2016 Oct 15;434:108-15. doi: 10.1016/j.mce.2016.06.013. Epub 2016 Jun 18.
115 Effect of alkylglycerone phosphate synthase on the expression profile of circRNAs in the human thyroid cancer cell line FRO.Oncol Lett. 2018 May;15(5):7889-7899. doi: 10.3892/ol.2018.8356. Epub 2018 Mar 26.
116 Silencing of A-Kinase Anchor Protein 4 (AKAP4) Inhibits Proliferation and Progression of Thyroid Cancer.Oncol Res. 2017 Jul 5;25(6):873-878. doi: 10.3727/096504016X14783701102564. Epub 2016 Nov 8.
117 Anoctamin5 regulates cell migration and invasion in thyroid cancer.Int J Oncol. 2017 Oct;51(4):1311-1319. doi: 10.3892/ijo.2017.4113. Epub 2017 Sep 1.
118 Comprehensive analysis of the clinical significance and prospective molecular mechanisms of differentially expressed autophagy-related genes in thyroid cancer.Int J Oncol. 2018 Aug;53(2):603-619. doi: 10.3892/ijo.2018.4404. Epub 2018 May 11.
119 Restoration of Brain Acid Soluble Protein 1 Inhibits Proliferation and Migration of Thyroid Cancer Cells.Chin Med J (Engl). 2016 Jun 20;129(12):1439-46. doi: 10.4103/0366-6999.183434.
120 The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1.Cell Death Dis. 2018 Aug 29;9(9):871. doi: 10.1038/s41419-018-0933-y.
121 Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-B pathways.Braz J Med Biol Res. 2017 Jan 16;50(1):e5933. doi: 10.1590/1414-431X20165933.
122 C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.Biochem Biophys Res Commun. 2017 Jan 22;482(4):590-596. doi: 10.1016/j.bbrc.2016.11.078. Epub 2016 Nov 15.
123 Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?.Front Endocrinol (Lausanne). 2018 Jun 21;9:314. doi: 10.3389/fendo.2018.00314. eCollection 2018.
124 CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer.Oncol Lett. 2018 Jul;16(1):105-112. doi: 10.3892/ol.2018.8653. Epub 2018 May 7.
125 Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.Cancer Lett. 2017 Dec 1;410:201-211. doi: 10.1016/j.canlet.2017.09.024. Epub 2017 Sep 23.
126 Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.Oncotarget. 2016 Sep 6;7(36):57978-57990. doi: 10.18632/oncotarget.11154.
127 Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.Medicine (Baltimore). 2016 Jan;95(4):e2592. doi: 10.1097/MD.0000000000002592.
128 Loss of HITS (FAM107B) expression in cancers of multiple organs: tissue microarray analysis.Int J Oncol. 2012 Oct;41(4):1347-57. doi: 10.3892/ijo.2012.1550. Epub 2012 Jul 10.
129 An integrated analysis of cancer genes in thyroid cancer.Oncol Rep. 2016 Feb;35(2):962-70. doi: 10.3892/or.2015.4466. Epub 2015 Dec 1.
130 Case Report of Birt-Hogg-Dub Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.Medicine (Baltimore). 2016 May;95(22):e3695. doi: 10.1097/MD.0000000000003695.
131 Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.Oncotarget. 2017 Apr 11;8(15):24457-24468. doi: 10.18632/oncotarget.14904.
132 Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway.Cancer Biol Ther. 2018;19(12):1139-1152. doi: 10.1080/15384047.2018.1480888. Epub 2018 Sep 12.
133 Knockdown of GATAD2A suppresses cell proliferation in thyroid cancer invitro.Oncol Rep. 2017 Apr;37(4):2147-2152. doi: 10.3892/or.2017.5436. Epub 2017 Feb 10.
134 Elevated HMGN4 expression potentiates thyroid tumorigenesis.Carcinogenesis. 2017 Apr 1;38(4):391-401. doi: 10.1093/carcin/bgx015.
135 Induction of epithelial-mesenchymal transition (EMT) by Beclin 1 knockdown via posttranscriptional upregulation of ZEB1 in thyroid cancer cells.Oncotarget. 2016 Oct 25;7(43):70364-70377. doi: 10.18632/oncotarget.12217.
136 HORMAD2 methylation-mediated epigenetic regulation of gene expression in thyroid cancer.J Cell Mol Med. 2018 Oct;22(10):4640-4652. doi: 10.1111/jcmm.13680. Epub 2018 Jul 24.
137 Tumour suppressive function of HUWE1 in thyroid cancer.J Biosci. 2016 Sep;41(3):395-405. doi: 10.1007/s12038-016-9623-z.
138 Loss-of-function of IFT88 determines metabolic phenotypes in thyroid cancer.Oncogene. 2018 Aug;37(32):4455-4474. doi: 10.1038/s41388-018-0211-6. Epub 2018 May 10.
139 THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2307-2312. doi: 10.1073/pnas.1614265114. Epub 2017 Feb 13.
140 IL-17RB enhances thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression.Mol Immunol. 2017 Oct;90:126-135. doi: 10.1016/j.molimm.2017.06.034. Epub 2017 Jul 15.
141 Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway.Biomed Pharmacother. 2018 Feb;98:265-270. doi: 10.1016/j.biopha.2017.12.045. Epub 2017 Dec 27.
142 Activating KIR2DS5 receptor is a risk for thyroid cancer.Hum Immunol. 2012 Oct;73(10):1017-22. doi: 10.1016/j.humimm.2012.07.325. Epub 2012 Jul 23.
143 Coupling of LETM1 up-regulation with oxidative phosphorylation and platelet-derived growth factor receptor signaling via YAP1 transactivation.Oncotarget. 2016 Oct 11;7(41):66728-66739. doi: 10.18632/oncotarget.11456.
144 LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer.Biochem Biophys Res Commun. 2018 Sep 3;503(1):257-263. doi: 10.1016/j.bbrc.2018.06.012. Epub 2018 Jun 11.
145 MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling.Biochem Biophys Res Commun. 2017 Sep 9;491(1):72-78. doi: 10.1016/j.bbrc.2017.07.044. Epub 2017 Jul 8.
146 A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma.Onco Targets Ther. 2018 Jan 11;11:307-311. doi: 10.2147/OTT.S154158. eCollection 2018.
147 E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin.Cell Death Dis. 2018 Sep 24;9(10):987. doi: 10.1038/s41419-018-1001-3.
148 Downregulation of Notch-regulated Ankyrin Repeat Protein Exerts Antitumor Activities against Growth of Thyroid Cancer.Chin Med J (Engl). 2016 Jul 5;129(13):1544-52. doi: 10.4103/0366-6999.184465.
149 Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.J Clin Endocrinol Metab. 2017 Feb 1;102(2):613-624. doi: 10.1210/jc.2016-1677.
150 Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation.Cell Commun Signal. 2019 Feb 13;17(1):12. doi: 10.1186/s12964-019-0322-x.
151 Poly r(C) binding protein (PCBP) 1 expression is regulated at the post-translation level in thyroid carcinoma.Am J Transl Res. 2017 Feb 15;9(2):708-714. eCollection 2017.
152 Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na(131)I/5-FC on human thyroid cancer.Oncol Lett. 2017 Dec;14(6):7431-7436. doi: 10.3892/ol.2017.7175. Epub 2017 Oct 12.
153 Differential expression of PIWIL2 in papillary thyroid cancers.Gene. 2018 Apr 5;649:8-13. doi: 10.1016/j.gene.2018.01.066. Epub 2018 Jan 31.
154 A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers.Fam Cancer. 2017 Oct;16(4):561-566. doi: 10.1007/s10689-017-9984-y.
155 The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population.Thyroid. 2015 Mar;25(3):333-40. doi: 10.1089/thy.2014.0431. Epub 2015 Feb 5.
156 Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells.Cancer Res. 2016 Feb 1;76(3):582-93. doi: 10.1158/0008-5472.CAN-15-1199. Epub 2015 Nov 25.
157 MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/-Catenin Pathway in Thyroid Cancer.Med Sci Monit. 2017 Oct 12;23:4885-4894. doi: 10.12659/msm.906997.
158 RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.Onco Targets Ther. 2017 Jan 9;10:247-257. doi: 10.2147/OTT.S124417. eCollection 2017.
159 A somatic mutation of RasGRP3 decreases Na(+)/I(-) symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway.Am J Cancer Res. 2018 Sep 1;8(9):1847-1855. eCollection 2018.
160 Analysis of ribonuclease activity in sub-nanoliter droplets by label-free fluorescence measurements.Analyst. 2017 Jul 10;142(14):2610-2616. doi: 10.1039/c6an02724e.
161 Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor- type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.Cancer Sci. 2018 Mar;109(3):642-655. doi: 10.1111/cas.13478. Epub 2018 Feb 1.
162 LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer.Cancer Gene Ther. 2018 Feb;25(1-2):39-46. doi: 10.1038/s41417-017-0003-0. Epub 2017 Dec 12.
163 HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.BMC Med Genet. 2016 Aug 17;17(1):60. doi: 10.1186/s12881-016-0323-1.
164 Effect of Interferon- on the Basal and the TNF-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.Mediators Inflamm. 2016;2016:8512417. doi: 10.1155/2016/8512417. Epub 2016 Jul 31.
165 Silencing of TCTN1 inhibits proliferation, induces cell cycle arrest and apoptosis in human thyroid cancer.Exp Ther Med. 2017 Oct;14(4):3720-3726. doi: 10.3892/etm.2017.4940. Epub 2017 Aug 16.
166 Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
167 Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.Clin Cancer Res. 2016 Sep 1;22(17):4491-504. doi: 10.1158/1078-0432.CCR-15-2461. Epub 2016 Mar 30.
168 Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214.Int J Oncol. 2017 Feb;50(2):708-716. doi: 10.3892/ijo.2016.3803. Epub 2016 Dec 14.
169 TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.Oncol Rep. 2017 Mar;37(3):1555-1564. doi: 10.3892/or.2017.5364. Epub 2017 Jan 13.
170 Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/-catenin signaling pathway.Biomed Pharmacother. 2017 Dec;96:98-103. doi: 10.1016/j.biopha.2017.09.132. Epub 2017 Sep 29.
171 Correlation of 18F-FDG uptake and thyroid cancer stem cells.Q J Nucl Med Mol Imaging. 2020 Dec;64(4):393-399. doi: 10.23736/S1824-4785.18.03088-1. Epub 2018 Aug 28.
172 Rewiring of the apoptotic TGF--SMAD/NFB pathway through an oncogenic function of p27 in human papillary thyroid cancer.Oncogene. 2017 Feb 2;36(5):652-666. doi: 10.1038/onc.2016.233. Epub 2016 Jul 25.
173 A nested case-control study of polychlorinated biphenyls, organochlorine pesticides, and thyroid cancer in the Janus Serum Bank cohort.Environ Res. 2018 Aug;165:125-132. doi: 10.1016/j.envres.2018.04.012. Epub 2018 Apr 23.
174 Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma.J Steroid Biochem Mol Biol. 2016 May;159:26-30. doi: 10.1016/j.jsbmb.2016.02.016. Epub 2016 Feb 22.
175 Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.
176 Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.Int J Cancer. 2018 Oct 1;143(7):1706-1719. doi: 10.1002/ijc.31548. Epub 2018 May 7.
177 Steroid receptor coactivator-1 interacts with NF-B to increase VEGFC levels in human thyroid cancer.Biosci Rep. 2018 Jun 12;38(3):BSR20180394. doi: 10.1042/BSR20180394. Print 2018 Jun 29.
178 Gene master regulators of papillary and anaplastic thyroid cancers.Oncotarget. 2017 Dec 19;9(2):2410-2424. doi: 10.18632/oncotarget.23417. eCollection 2018 Jan 5.
179 Pictorial Representation of Illness and Self Measure-Revised 2 (PRISM-R2): an effective tool to assess perceived burden of thyroid cancer in mainland China.Support Care Cancer. 2018 Sep;26(9):3267-3275. doi: 10.1007/s00520-018-4172-7. Epub 2018 Apr 11.
180 PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.J Biomed Nanotechnol. 2014 Jul;10(7):1249-58. doi: 10.1166/jbn.2014.1862.
181 EBP1 suppresses growth, migration, and invasion of thyroid cancer cells through upregulating RASAL expression.Tumour Biol. 2015 Nov;36(11):8325-31. doi: 10.1007/s13277-015-3523-y. Epub 2015 May 26.
182 The high expression of TC1 (C8orf4) was correlated with the expression of -catenin and cyclin D1 and the progression of squamous cell carcinomas of the tongue.Tumour Biol. 2015 Sep;36(9):7061-7. doi: 10.1007/s13277-015-3423-1. Epub 2015 Apr 14.
183 Effect of ABCE1-silencing gene, transfected by electrotransfer, on the proliferation, invasion, and migration of human thyroid carcinoma SW579 cells.Genet Mol Res. 2015 Nov 23;14(4):14680-9. doi: 10.4238/2015.November.18.32.
184 CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.Oncogene. 2013 May 30;32(22):2726-38. doi: 10.1038/onc.2012.301. Epub 2012 Jul 16.
185 Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?.Med Sci Monit. 2015 Jun 16;21:1745-51. doi: 10.12659/MSM.893597.
186 MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.Biochem Biophys Res Commun. 2015 Sep 4;464(4):1128-1133. doi: 10.1016/j.bbrc.2015.07.090. Epub 2015 Jul 20.
187 CCNG2 suppressor biological effects on thyroid cancer cell through promotion of CDK2 degradation.Asian Pac J Cancer Prev. 2013;14(10):6165-71. doi: 10.7314/apjcp.2013.14.10.6165.
188 Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.J Clin Endocrinol Metab. 2014 Jul;99(7):E1173-82. doi: 10.1210/jc.2013-4140. Epub 2014 Mar 21.
189 X-ray repair cross-complementing group 1(XRCC1) genetic polymorphisms and thyroid carcinoma risk: a meta-analysis.Asian Pac J Cancer Prev. 2012;13(12):6385-90. doi: 10.7314/apjcp.2012.13.12.6385.
190 Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to 131I.Nucl Med Commun. 2014 Sep;35(9):932-8. doi: 10.1097/MNM.0000000000000142.
191 DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.Anticancer Res. 2013 Nov;33(11):4833-9.
192 FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1.Endocr Relat Cancer. 2020 Mar;27(3):137-151. doi: 10.1530/ERC-19-0156.
193 The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression.Oncogene. 2012 Sep 6;31(36):4012-21. doi: 10.1038/onc.2011.569. Epub 2011 Dec 12.
194 Helicase-like transcription factor: a new marker of well-differentiated thyroid cancers.BMC Cancer. 2014 Jul 8;14:492. doi: 10.1186/1471-2407-14-492.
195 HOXC10 up-regulation contributes to human thyroid cancer and indicates poor survival outcome.Mol Biosyst. 2015 Nov;11(11):2946-54. doi: 10.1039/c5mb00253b.
196 Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.BMC Cancer. 2013 Oct 8;13:462. doi: 10.1186/1471-2407-13-462.
197 microRNA-106b-mediated down-regulation of C1orf24 expression induces apoptosis and suppresses invasion of thyroid cancer.Oncotarget. 2015 Sep 29;6(29):28357-70. doi: 10.18632/oncotarget.4947.
198 DNA methylation signatures identify biologically distinct thyroid cancer subtypes.J Clin Endocrinol Metab. 2013 Jul;98(7):2811-21. doi: 10.1210/jc.2012-3566. Epub 2013 May 10.
199 Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.Mol Cancer. 2013 Oct 20;12(1):124. doi: 10.1186/1476-4598-12-124.
200 REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.Oncotarget. 2015 Nov 17;6(36):39211-24. doi: 10.18632/oncotarget.5391.
201 RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.J Clin Endocrinol Metab. 2013 Mar;98(3):E446-54. doi: 10.1210/jc.2012-3180. Epub 2013 Feb 7.
202 SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12276-83. eCollection 2015.
203 Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer.J Clin Endocrinol Metab. 2013 Aug;98(8):E1334-44. doi: 10.1210/jc.2013-1053. Epub 2013 May 29.
204 Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.Chin Med J (Engl). 2012 Oct;125(19):3526-31.
205 SPC24 is critical for anaplastic thyroid cancer progression.Oncotarget. 2017 Mar 28;8(13):21884-21891. doi: 10.18632/oncotarget.15670.
206 Novel antiapoptotic effect of TBX15: overexpression of TBX15 reduces apoptosis in cancer cells.Apoptosis. 2015 Oct;20(10):1338-46. doi: 10.1007/s10495-015-1155-8.
207 Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion.Endocr Relat Cancer. 2008 Sep;15(3):787-99. doi: 10.1677/ERC-08-0079. Epub 2008 Jun 17.
208 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.J Clin Invest. 2005 Jan;115(1):94-101. doi: 10.1172/JCI23237.
209 The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.Clin Cancer Res. 2007 Aug 15;13(16):4713-20. doi: 10.1158/1078-0432.CCR-07-0618.
210 Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.J Biol Chem. 2007 May 25;282(21):15490-7. doi: 10.1074/jbc.M610586200. Epub 2007 Apr 4.
211 Knockdown of BAG3 induces epithelial-mesenchymal transition in thyroid cancer cells through ZEB1 activation.Cell Death Dis. 2014 Feb 27;5(2):e1092. doi: 10.1038/cddis.2014.32.
212 The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.Cancer Lett. 2015 Feb 28;357(2):535-41. doi: 10.1016/j.canlet.2014.12.010. Epub 2014 Dec 9.
213 CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.Endocr Relat Cancer. 2011 Nov 28;18(6):731-42. doi: 10.1530/ERC-11-0181. Print 2011.
214 GINS2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating CITED2 and LOXL2.Cancer Gene Ther. 2019 Mar;26(3-4):103-113. doi: 10.1038/s41417-018-0045-y. Epub 2018 Sep 4.
215 Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.J Exp Clin Cancer Res. 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3.
216 CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.Cancer Res. 2008 Sep 1;68(17):7156-64. doi: 10.1158/0008-5472.CAN-08-1085.
217 Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling.Oncotarget. 2016 Apr 5;7(14):17957-69. doi: 10.18632/oncotarget.7647.
218 The role of EIF1AX in thyroid cancer tumourigenesis and progression.J Endocrinol Invest. 2019 Mar;42(3):313-318. doi: 10.1007/s40618-018-0919-8. Epub 2018 Jul 2.
219 Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.J Clin Endocrinol Metab. 2011 Mar;96(3):E554-65. doi: 10.1210/jc.2010-1800. Epub 2010 Dec 29.
220 Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway.Oncol Rep. 2018 Aug;40(2):859-866. doi: 10.3892/or.2018.6502. Epub 2018 Jun 18.
221 INT-2 gene amplification in differentiated human thyroid cancer.Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4. doi: 10.1055/s-0029-1211713.
222 Oleanolic acid inhibits cell proliferation migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A.Anticancer Drugs. 2019 Sep;30(8):812-820. doi: 10.1097/CAD.0000000000000777.
223 The Effect of Hexavalent Chromium on the Incidence and Mortality of Human Cancers: A Meta-Analysis Based on Published Epidemiological Cohort Studies.Front Oncol. 2019 Feb 4;9:24. doi: 10.3389/fonc.2019.00024. eCollection 2019.
224 Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.J Surg Oncol. 2012 Mar 15;105(4):357-64. doi: 10.1002/jso.22113. Epub 2011 Oct 17.
225 Improved determination of variant erythrocytes at the glycophorin A (GPA) locus and variant frequency in patients treated with radioiodine for thyroid cancer.Int J Radiat Biol. 1996 Aug;70(2):131-43. doi: 10.1080/095530096145120.
226 Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.Clin Endocrinol (Oxf). 2017 Jun;86(6):837-844. doi: 10.1111/cen.13316. Epub 2017 Mar 23.
227 Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.Int J Cancer. 2020 Jan 15;146(2):521-530. doi: 10.1002/ijc.32622. Epub 2019 Aug 28.
228 Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.J Clin Endocrinol Metab. 2006 Mar;91(3):1119-28. doi: 10.1210/jc.2005-1826. Epub 2006 Jan 4.
229 Expression of insulin-like growth factor I (IGF-I) gene and of genes for IGF-binding proteins 1, 2, 3, 4 (IGFBP-1-IGFBP-4) in non-neoplastic human thyroid cells and in certain human thyroid cancers. Effect of exogenous IGF-I on this expression.Endocr Res. 2004 Feb;30(1):47-59. doi: 10.1081/erc-120028484.
230 Suppression of Tafazzin promotes thyroid cancer apoptosis via activating the JNK signaling pathway and enhancing INF2-mediated mitochondrial fission.J Cell Physiol. 2019 Sep;234(9):16238-16251. doi: 10.1002/jcp.28287. Epub 2019 Feb 11.
231 INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor.Cancer Discov. 2015 Jul;5(7):730-9. doi: 10.1158/2159-8290.CD-14-1329. Epub 2015 Apr 16.
232 MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways.J Cell Physiol. 2019 Aug;234(10):18382-18391. doi: 10.1002/jcp.28472. Epub 2019 Apr 2.
233 Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
234 KLLN epigenotype-phenotype associations in Cowden syndrome.Eur J Hum Genet. 2015 Nov;23(11):1538-43. doi: 10.1038/ejhg.2015.8. Epub 2015 Feb 11.
235 Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.J Clin Endocrinol Metab. 2009 Apr;94(4):1467-71. doi: 10.1210/jc.2008-2378. Epub 2009 Feb 3.
236 Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.Cancer Lett. 2019 Feb 1;442:362-372. doi: 10.1016/j.canlet.2018.11.010. Epub 2018 Nov 14.
237 Survey of dentin sialophosphoprotein and its cognate matrix metalloproteinase-20 in human cancers.Cancer Med. 2019 May;8(5):2167-2178. doi: 10.1002/cam4.2117. Epub 2019 Apr 1.
238 Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.J Clin Endocrinol Metab. 2006 Jul;91(7):2704-12. doi: 10.1210/jc.2006-0492. Epub 2006 Apr 18.
239 HLA-DR alpha gene regulation in immortalized human thyroid cancer cells.Clin Immunol Immunopathol. 1993 May;67(2):151-6. doi: 10.1006/clin.1993.1058.
240 Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression.Am J Transl Res. 2019 Mar 15;11(3):1760-1770. eCollection 2019.
241 Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer.BMC Cancer. 2011 Jan 12;11:14. doi: 10.1186/1471-2407-11-14.
242 Human herpes simplex viruses in benign and malignant thyroid tumours.J Pathol. 2010 Jun;221(2):193-200. doi: 10.1002/path.2701.
243 Two-dimensional complementary deoxyribonucleic acid electrophoresis revealing up-regulated human epididymal protein-1 and down-regulated CL-100 in thyroid papillary carcinoma.Endocrinology. 2002 Nov;143(11):4422-8. doi: 10.1210/en.2002-220550.
244 Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.Cancer Res. 2006 Feb 1;66(3):1491-9. doi: 10.1158/0008-5472.CAN-05-2514.
245 Expression of the ring ligase PRAJA2 in thyroid cancer.J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.
246 Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34.Nutr Cancer. 2010;62(1):66-73. doi: 10.1080/01635580903191569.
247 Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.Thyroid. 2011 Apr;21(4):391-9. doi: 10.1089/thy.2010.0168.
248 RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism.Cell Signal. 2006 Dec;18(12):2272-82. doi: 10.1016/j.cellsig.2006.05.016. Epub 2006 May 24.
249 Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?.Neoplasma. 2007;54(1):57-62.
250 Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.Oncogene. 2017 Sep 14;36(37):5296-5308. doi: 10.1038/onc.2017.154. Epub 2017 May 15.
251 RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.J Endocrinol Invest. 2008 Oct;31(10):893-9. doi: 10.1007/BF03346438.
252 RAIN Is a Novel Enhancer-Associated lncRNA That Controls RUNX2 Expression and Promotes Breast and Thyroid Cancer.Mol Cancer Res. 2020 Jan;18(1):140-152. doi: 10.1158/1541-7786.MCR-19-0564. Epub 2019 Oct 17.
253 Frequent epigenetic inactivation of RASSF10 in thyroid cancer.Epigenetics. 2009 Nov 16;4(8):571-6. doi: 10.4161/epi.4.8.10056. Epub 2009 Nov 14.
254 Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.Mol Cancer. 2010 Sep 29;9:264. doi: 10.1186/1476-4598-9-264.
255 RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer.J Clin Endocrinol Metab. 2007 Apr;92(4):1458-66. doi: 10.1210/jc.2006-2199. Epub 2007 Jan 23.
256 RCAN1-4 is a thyroid cancer growth and metastasis suppressor.JCI Insight. 2017 Mar 9;2(5):e90651. doi: 10.1172/jci.insight.90651.
257 Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.PLoS One. 2010 Sep 22;5(9):e12701. doi: 10.1371/journal.pone.0012701.
258 Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells.Mol Cancer Res. 2011 Jun;9(6):673-87. doi: 10.1158/1541-7786.MCR-10-0411. Epub 2011 Apr 14.
259 The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma.Mol Cancer. 2009 Jul 30;8:52. doi: 10.1186/1476-4598-8-52.
260 Modern approaches to age-old questions about thyroid tumors.Thyroid. 2005 Jun;15(6):575-82. doi: 10.1089/thy.2005.15.575.
261 Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer.Endocr Relat Cancer. 2015 Apr;22(2):121-30. doi: 10.1530/ERC-14-0537.
262 Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer. Am J Hum Genet. 2015 Nov 5;97(5):661-76. doi: 10.1016/j.ajhg.2015.10.001. Epub 2015 Oct 29.
263 Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells.BMC Cancer. 2013 Dec 5;13:574. doi: 10.1186/1471-2407-13-574.
264 Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.Oncotarget. 2017 Aug 24;8(61):103014-103031. doi: 10.18632/oncotarget.20488. eCollection 2017 Nov 28.
265 SIRT4 inhibits the proliferation, migration, and invasion abilities of thyroid cancer cells by inhibiting glutamine metabolism.Onco Targets Ther. 2019 Mar 28;12:2397-2408. doi: 10.2147/OTT.S189536. eCollection 2019.
266 SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.Oncogene. 2019 Jan;38(3):345-359. doi: 10.1038/s41388-018-0434-6. Epub 2018 Aug 9.
267 Thyroid tumorigenesis and molecular markers in thyroid cancer.Curr Opin Oncol. 2010 Jan;22(1):23-9. doi: 10.1097/CCO.0b013e328333846f.
268 miR-4319 inhibited the development of thyroid cancer by modulating FUS-stabilized SMURF1.J Cell Biochem. 2020 Jan;121(1):174-182. doi: 10.1002/jcb.29026. Epub 2019 May 30.
269 Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression.J Pathol. 2017 Nov;243(3):342-353. doi: 10.1002/path.4951.
270 Ras oncogene-mediated progressive silencing of extracellular superoxide dismutase in tumorigenesis.Biomed Res Int. 2015;2015:780409. doi: 10.1155/2015/780409. Epub 2015 Oct 15.
271 Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer.J Clin Endocrinol Metab. 2009 Nov;94(11):4613-8. doi: 10.1210/jc.2009-0703. Epub 2009 Oct 9.
272 Expression of SSX genes in human tumors.Int J Cancer. 1998 Jul 3;77(1):19-23. doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2.
273 Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.Am J Pathol. 2018 Nov;188(11):2653-2661. doi: 10.1016/j.ajpath.2018.07.012. Epub 2018 Aug 18.
274 Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC Cancer. 2006 Nov 1;6:260. doi: 10.1186/1471-2407-6-260.
275 Genetic markers to discriminate benign and malignant thyroid nodules with undetermined cytology in an area of borderline iodine deficiency.J Endocrinol Invest. 2012 Sep;35(8):754-9. doi: 10.3275/8012. Epub 2011 Oct 4.
276 Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.J Cancer Res Clin Oncol. 2007 Apr;133(4):213-8. doi: 10.1007/s00432-006-0159-8. Epub 2006 Oct 28.
277 Oncometabolites as biomarkers in thyroid cancer: a systematic review.Cancer Manag Res. 2019 Feb 25;11:1829-1841. doi: 10.2147/CMAR.S188661. eCollection 2019.
278 Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC).Bosn J Basic Med Sci. 2019 May 20;19(2):146-154. doi: 10.17305/bjbms.2018.2865.
279 Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.Cancer Res. 2001 May 1;61(9):3640-6.
280 Downregulated long noncoding RNA LINC00313 inhibits the epithelial-mesenchymal transition, invasion, and migration of thyroid cancer cells through inhibiting the methylation of ALX4.J Cell Physiol. 2019 Nov;234(11):20992-21004. doi: 10.1002/jcp.28703. Epub 2019 May 15.
281 Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression.Endocr Metab Immune Disord Drug Targets. 2020;20(4):591-598. doi: 10.2174/1871530319666191018170022.
282 Serum deprivation response functions as a tumor suppressor gene in papillary thyroid cancer.Clin Genet. 2019 Nov;96(5):418-428. doi: 10.1111/cge.13609. Epub 2019 Jul 31.
283 Generation and identification of a thyroid cancer cell line with stable expression of CCDC67 and luciferase reporter genes.Oncol Lett. 2019 Nov;18(5):4495-4502. doi: 10.3892/ol.2019.10839. Epub 2019 Sep 10.
284 Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.Recent Pat Anticancer Drug Discov. 2019;14(3):226-241. doi: 10.2174/1574892814666190726143011.
285 Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Oncotarget. 2017 Apr 18;8(16):27075-27092. doi: 10.18632/oncotarget.15635.
286 Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.Biomed Pharmacother. 2019 Aug;116:108966. doi: 10.1016/j.biopha.2019.108966. Epub 2019 May 16.
287 IGSF1: A novel oncogene regulates the thyroid cancer progression.Cell Biochem Funct. 2019 Oct;37(7):516-524. doi: 10.1002/cbf.3426. Epub 2019 Jul 25.
288 Knockdown of IQGAP1 inhibits proliferation and epithelial-mesenchymal transition by Wnt/-catenin pathway in thyroid cancer.Onco Targets Ther. 2017 Mar 13;10:1549-1559. doi: 10.2147/OTT.S128564. eCollection 2017.
289 Comprehensive Exploration to Identify Predictive DNA Markers of Np63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma.Ann Surg Oncol. 2019 Dec;26(13):4814-4825. doi: 10.1245/s10434-019-07795-w. Epub 2019 Sep 16.
290 A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis.Cancer Res. 2019 Nov 15;79(22):5746-5757. doi: 10.1158/0008-5472.CAN-19-0039. Epub 2019 Sep 26.
291 LIMD2 targeted by miR?4a promotes the proliferation and invasion of nonsmall cell lung cancer cells.Mol Med Rep. 2018 Nov;18(5):4760-4766. doi: 10.3892/mmr.2018.9464. Epub 2018 Sep 6.
292 LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.Int J Oncol. 2018 Apr;52(4):1189-1197. doi: 10.3892/ijo.2018.4273. Epub 2018 Feb 9.
293 Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy.J Photochem Photobiol B. 2019 Aug;197:111534. doi: 10.1016/j.jphotobiol.2019.111534. Epub 2019 Jun 15.
294 MicroRNA-592 suppresses the malignant phenotypes of thyroid cancer by regulating lncRNA NEAT1 and downregulating NOVA1.Int J Mol Med. 2019 Sep;44(3):1172-1182. doi: 10.3892/ijmm.2019.4278. Epub 2019 Jul 16.
295 Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.Mutat Res. 2019 Nov;816-818:111672. doi: 10.1016/j.mrfmmm.2019.111672. Epub 2019 Jun 1.
296 Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.Cancers (Basel). 2018 Mar 27;10(4):92. doi: 10.3390/cancers10040092.
297 Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression.Oncol Lett. 2019 Sep;18(3):3227-3235. doi: 10.3892/ol.2019.10632. Epub 2019 Jul 18.
298 REG potentiates TGF-/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells.Cell Signal. 2019 Dec;64:109412. doi: 10.1016/j.cellsig.2019.109412. Epub 2019 Sep 3.
299 miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B.J Cell Biochem. 2019 Nov;120(11):18927-18936. doi: 10.1002/jcb.29213. Epub 2019 Jun 27.
300 Rap1GAP alters leukemia cell differentiation, apoptosis and invasion invitro.Oncol Rep. 2012 Aug;28(2):622-8. doi: 10.3892/or.2012.1825. Epub 2012 May 18.
301 MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2.Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):232-240. doi: 10.26355/eurrev_201901_16769.
302 Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway.Oncol Lett. 2019 Jul;18(1):637-644. doi: 10.3892/ol.2019.10391. Epub 2019 May 21.
303 TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.Cell Death Dis. 2019 May 21;10(6):397. doi: 10.1038/s41419-019-1600-7.
304 TFCP2/TFCP2L1/UBP1 transcription factors in cancer.Cancer Lett. 2018 Apr 28;420:72-79. doi: 10.1016/j.canlet.2018.01.078. Epub 2018 Feb 7.
305 TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.Biomed Pharmacother. 2019 Dec;120:109508. doi: 10.1016/j.biopha.2019.109508. Epub 2019 Oct 22.